Payment overview · 2025
General Payments
$358.39
20 reported records · 12 companies
Healthcare provider profile · identity verified
Joseph H Munning, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JASPER, IN · NPI 1427016336
Verified facts
What the public records show
CMS Open Payments records show Joseph H Munning, M.D. received $358.39 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.53 | 22.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.05 | 12.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.37 | 10.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.47 | 8.2% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $27.86 | 7.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.24 | 7.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.62 | 5.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.89 | 5.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.46 | 5.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.73 | 5.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.35 | 4.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.82 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $358.39 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.55 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.55 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $45.05 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.98 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.47 | 2 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $27.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.24 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
162 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 661 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 518 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 373 | 86 |
| Losartan Potassium | Losartan Potassium | 366 | 93 |
| Lisinopril | Lisinopril | 355 | 91 |
| Furosemide | Furosemide | 342 | 91 |
| Metformin Hcl | Metformin Hcl | 274 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 258 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 254 | 68 |
| Omeprazole | Omeprazole | 249 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 68 |
| Simvastatin | Simvastatin | 245 | 62 |
| Gabapentin | Gabapentin | 231 | 62 |
| Carvedilol | Carvedilol | 230 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 68 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 38 |
| Atenolol | Atenolol | 193 | 48 |
| Allopurinol | Allopurinol | 176 | 52 |
| Jardiance | Empagliflozin | 166 | 38 |
| Lorazepam | Lorazepam | 165 | 33 |
| Eliquis | Apixaban | 162 | 38 |
| Glimepiride | Glimepiride | 159 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 145 | 37 |
| Sertraline Hcl | Sertraline Hcl | 139 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 37 |
| Tramadol Hcl | Tramadol Hcl | 132 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 36 |
| Potassium Chloride | Potassium Chloride | 127 | 32 |
| Finasteride | Finasteride | 120 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 34 |
| Spironolactone | Spironolactone | 106 | 23 |
| Meloxicam | Meloxicam | 100 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 99 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 27 |
| Alendronate Sodium | Alendronate Sodium | 88 | 22 |
| Donepezil Hcl | Donepezil Hcl | 86 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 25 |
| Prednisone | Prednisone | 81 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 16 |
| Famotidine | Famotidine | 69 | 16 |
| Buspirone Hcl | Buspirone Hcl | 67 | 13 |
| Clonazepam | Clonazepam | 67 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 14 |
| Trazodone Hcl | Trazodone Hcl | 63 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 11 |
| Cephalexin | Cephalexin | 58 | 31 |
| Montelukast Sodium | Montelukast Sodium | 58 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Torsemide | Torsemide | 46 | 11 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Mirtazapine | Mirtazapine | 45 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Chlorthalidone | Chlorthalidone | 42 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | 11 |
| Estradiol | Estradiol | 41 | 11 |
| Celecoxib | Celecoxib | 39 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 33 |
| Bumetanide | Bumetanide | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Klor-Con M10 | Potassium Chloride | 31 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 19 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Rybelsus | Semaglutide | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 16 |
| Diazepam | Diazepam | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Keppra Xr | Levetiracetam | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $358.39 · 20 records | Novo Nordisk Inc | Auvelity, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, MINIMED 780G, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE, ZURZUVAE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error